Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
MQV
Very Strong
GARP
Very Strong
MQV Small
Neutral
Momentum
Price
Weak
Earnings
Very Strong
Growth
Earnings
Very Strong
Dividends
Very Strong
Quality
Capital Efficiency
Very Strong
Balance Sheet
Very Strong
Website
N/ATelephone
N/A
Address
Description
Anatara Lifesciences Ltd. engages in the development of non-antibiotic oral solutions for gastrointestinal diseases in animals and humans. It also develops and commercializes Detach, a non-antibiotic therapy that prevents and treats diarrhea in piglets. The company was founded by Tracey Mynott on July 15, 2010 and is headquartered in Adelaide, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.02 - 0.05
Trade Value (12mth)
AU$1,808.00
1 week
-4.17%
1 month
-2.13%
YTD
109.09%
1 year
53.13%
All time high
1.66
EPS 3 yr Growth
-68.50%
EBITDA Margin
N/A
Operating Cashflow
-$1m
Free Cash Flow Return
-109.00%
ROIC
-126.80%
Interest Coverage
N/A
Quick Ratio
5.50
Shares on Issue (Fully Dilluted)
181m
HALO Sector
Healthcare
Next Company Report Date
02-Sep-25
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
Date | Announcements |
---|---|
30 August 24 |
GaRP Irritable Bowel Syndrome Clinical Trial Update
×
GaRP Irritable Bowel Syndrome Clinical Trial Update |
29 August 24 |
$626,000 received in R&D Tax Incentive for FY24
×
$626,000 received in R&D Tax Incentive for FY24 |
22 August 24 |
Appendix 4E & Financial Report 30 June 2024
×
Appendix 4E & Financial Report 30 June 2024 |
09 August 24 |
Notification regarding unquoted securities - ANR
×
Notification regarding unquoted securities - ANR |
30 July 24 |
Appendix 4C & Q4 FY24 Activities Report
×
Appendix 4C & Q4 FY24 Activities Report |
12 July 24 |
Change of Director's Interest Notice
×
Change of Director's Interest Notice |
11 July 24 |
Notification regarding unquoted securities - ANR
×
Notification regarding unquoted securities - ANR |
09 July 24 |
Application for quotation of securities - ANR
×
Application for quotation of securities - ANR |
05 July 24 |
Results of Meeting
×
Results of Meeting |
13 June 24 |
IBS Clinical Trial Stage 2 recruitment is proceeding well
×
IBS Clinical Trial Stage 2 recruitment is proceeding well |
03 June 24 |
Notice of General Meeting/Proxy Form
×
Notice of General Meeting/Proxy Form |
14 May 24 |
ANR- Cleansing Notice
×
ANR- Cleansing Notice |
07 May 24 |
Application for quotation of securities - ANR
×
Application for quotation of securities - ANR |
07 May 24 |
Notification regarding unquoted securities - ANR
×
Notification regarding unquoted securities - ANR |
01 May 24 |
Anatara successful placement for $1.0M
×
Anatara successful placement for $1.0M |
01 May 24 |
Proposed issue of securities - ANR
×
Proposed issue of securities - ANR |
30 April 24 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
29 April 24 |
Trading Halt
×
Trading Halt |
22 April 24 |
Change in substantial holding
×
Change in substantial holding |
09 April 24 |
Recruitment 5 sites for Pivotal IBS Clinical Trial Stage 2
×
Recruitment 5 sites for Pivotal IBS Clinical Trial Stage 2 |
29 February 24 |
Recruitment for Pivotal Phase II IBS Clinical Trial Stage 2
×
Recruitment for Pivotal Phase II IBS Clinical Trial Stage 2 |
28 February 24 |
Appendix 4D & Half Year Report 31 December 2023
×
Appendix 4D & Half Year Report 31 December 2023 |
24 January 24 |
Appendix 4C & Q2 FY24 Activities Report
×
Appendix 4C & Q2 FY24 Activities Report |
18 December 23 |
Anatara finalises Entitlement Issue
×
Anatara finalises Entitlement Issue |
18 December 23 |
Application for quotation of securities - ANR
×
Application for quotation of securities - ANR |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.